Navigation Links
InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010
Date:2/1/2010

n. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. Pirfenidone failed to achieve statistical significance on the primary endpoint in one of its two pivotal clinical trials and there can be no assurance that the regulatory authorities in either the United States or Europe will grant regulatory approval based upon these data, in combination with the other efficacy analyses and safety results the company has submitted in support of its NDA filing and currently intends to submit in support of its MAA filing. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail in the risk factors attached as Exhibit 99.3 to InterMune’s Form 8-K filed with the SEC on January 20, 2010, and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulatory approval process; (ii) risks related to failure to achieve the clinical trial results required to commercialize our product candidates; and (iii) risks related to timely patient enrollment and retention in clinical trials. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 8-K and InterMune's other periodic reports filed with the SEC.  InterMune undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in InterMune's expectations.  

SOURCE InterMune, Inc.

RELATED LINKS

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... and PITTSBURGH , July 27, 2015 ... it will hold its extraordinary general meeting of shareholders in ... PRGO ; TASE) at the Okura Hotel Amsterdam on ... (CET). Among other agenda items at the ... the approval, under article 2:107a of the Dutch Civil Code, ...
(Date:7/27/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/rq47bp/global_pressure ... Pressure Relief Devices Market 2015-2019" report to their ... to grow at a CAGR of 4.41% over the ... Market 2015-2019, has been prepared based on an in-depth ... covers the Americas, and the APAC and EMEA; it ...
(Date:7/27/2015)... PLEASANTON, Calif. , July 27, 2015  QT ... the "Group"), a global company engaged in the design, ... minimally invasive treatment of vascular disease, has entered into ... for up to US$13.14 million convertible bond investment. This ... help boost its growth to the next milestone. ...
Breaking Medicine Technology:Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 2Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 3Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 4Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 5Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 6Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 7Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 8Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 9Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 10Global Pressure Relief Devices Market 2015-2019 with ArjoHuntleigh, Hill-Rom, Paramount Bed Holdings & Stryker Dominating 2QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 2QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 3
... , SCOTTSDALE, Ariz. , Jan. 22 Matrixx Initiatives, ... financial results for the fiscal 2010 third quarter, ended December 31, ... January 25, 2010 . An earnings conference call will be held the ... AM ET . , To access the teleconference, please call (888) 452-4006 ...
... ... Called Ampyra, to Improve Walking for People With All Types of ... The U.S. Food and Drug Administration has approved the ... Therapeutics) for its ability to improve walking speed in people with ...
Cached Medicine Technology:Matrixx Initiatives, Inc. Sets Time for Discussion of Third Quarter Fiscal 2010 Financial Results 2Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 2Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 3Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 4Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 5Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 6
(Date:7/27/2015)... ... ... SupplyLogic, a marketing execution partner based in metro New York and Chicago has ... Founder and CEO Kevin Sherlock discusses the value in supply chain visibility by quoting ... it the closer you get to the ocean, the more seafood costs?’ Those of ...
(Date:7/27/2015)... ... July 27, 2015 , ... Boston IVF, the first Massachusetts egg ... educational "Happy Hour" on Nantucket Island for women who wish to learn more ... Lady Restaurant and Bar, 2 Chins Way, Nantucket Island 02554 from 4:30-6:30pm. , This ...
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... ... serving communities in and around Dallas, Texas, is announcing a joint charity effort ... support and employment resources for American veterans who are returning from overseas. , ...
(Date:7/27/2015)... AL (PRWEB) , ... July 27, 2015 , ... Standifer ... announcing a charity drive that will support Camp Conquest, a specialized camp for young ... Alabama. , Camp Conquest offers a five day and four night curriculum designed to ...
(Date:7/27/2015)... ... 27, 2015 , ... Premier Insurance Advisors, a full service ... charity and awareness event with the Houston chapter of NAMI, the National Alliance ... to bettering the lives of the millions of Americans affected by mental illness. ...
Breaking Medicine News(10 mins):Health News:SupplyLogic Releases First Executive Blog on Supply Chain Management Issues 2Health News:Boston IVF to Host Egg Freezing Event in Nantucket on August 6th at 4:30pm 2Health News:Boston IVF to Host Egg Freezing Event in Nantucket on August 6th at 4:30pm 3Health News:The Tedesco Agency of North Dallas and Non-Profit IAVA Announce Joint Charity Effort to Support American Veterans 2Health News:Standifer Insurance Group and Camp Conquest Plan Joint Charity Initiative to Assist Hospitalized Children Suffering from Burn Injuries 2Health News:Standifer Insurance Group and Camp Conquest Plan Joint Charity Initiative to Assist Hospitalized Children Suffering from Burn Injuries 3Health News:Premier Insurance and the National Alliance of Mental Health Launch Grassroots Charity Effort to Support Houston Residents with Developmental Challenges 2Health News:Premier Insurance and the National Alliance of Mental Health Launch Grassroots Charity Effort to Support Houston Residents with Developmental Challenges 3
... (Nasdaq: KOOL ), a leading supplier of innovative ... that J. Melville Engle, the Company,s Chief Executive Officer, has ... the total number of directors to six. , , ... in the healthcare industry, joined the Company as Chief Executive ...
... Show That NUVIGIL Improves Excessive Sleepiness Associated with Jet ... Cephalon, Inc. (Nasdaq: CEPH ) presented ... Tablets [C-IV] significantly improved wakefulness in people with excessive ... three data were presented today at the SLEEP 2009 ...
... 26 Convictions, Forfeiture of Over $7 Million, and Sharing of Over $4 ... Rapids , and Des Moines ... Iowa, June 10 On March 24, 2003, a corner drugstore in ... an Internet prescription from a doctor in Mississippi. Six years and ...
... Researchers at The Wistar Institute have defined a key ... process of aging. The study, published June 11 in ... of aging that could point toward new anti-aging strategies ... that a class of proteins called sirtuins promotes fitness ...
... ... ... College of American Pathologists unveiled its Health Care Reform Agenda, citing key policy issues ... improve patient care in the future., , , , ,The College,s agenda addresses a ...
... all family members is warranted: report , WEDNESDAY, June ... children can suffer too. , A new report from ... calls for health and social service professionals to pay ... their children. , Rather than treating only the depressed ...
Cached Medicine News:Health News:ThermoGenesis Appoints Chief Executive Officer J. Melville ('Mel') Engle to Board of Directors 2Health News:ThermoGenesis Appoints Chief Executive Officer J. Melville ('Mel') Engle to Board of Directors 3Health News:ThermoGenesis Appoints Chief Executive Officer J. Melville ('Mel') Engle to Board of Directors 4Health News:NUVIGIL Jet Lag Disorder Data Presented at the SLEEP 2009 23rd Annual Meeting of the Associated Professional Sleep Societies 2Health News:NUVIGIL Jet Lag Disorder Data Presented at the SLEEP 2009 23rd Annual Meeting of the Associated Professional Sleep Societies 3Health News:NUVIGIL Jet Lag Disorder Data Presented at the SLEEP 2009 23rd Annual Meeting of the Associated Professional Sleep Societies 4Health News:NUVIGIL Jet Lag Disorder Data Presented at the SLEEP 2009 23rd Annual Meeting of the Associated Professional Sleep Societies 5Health News:Record-Breaking Internet Pharmacy Prosecution Nets Millions for Iowa Law Enforcement 2Health News:Record-Breaking Internet Pharmacy Prosecution Nets Millions for Iowa Law Enforcement 3Health News:Record-Breaking Internet Pharmacy Prosecution Nets Millions for Iowa Law Enforcement 4Health News:Record-Breaking Internet Pharmacy Prosecution Nets Millions for Iowa Law Enforcement 5Health News:Record-Breaking Internet Pharmacy Prosecution Nets Millions for Iowa Law Enforcement 6Health News:Record-Breaking Internet Pharmacy Prosecution Nets Millions for Iowa Law Enforcement 7Health News:Record-Breaking Internet Pharmacy Prosecution Nets Millions for Iowa Law Enforcement 8Health News:Wistar Institute team finds key target of aging regulator 2Health News:CAP Announces Health Care Reform Agenda 2Health News:CAP Announces Health Care Reform Agenda 3Health News:If Mom or Dad Is Depressed, Kids Need Help Too 2Health News:If Mom or Dad Is Depressed, Kids Need Help Too 3
... For delivery of medication as well as ... refillable, closed dilution, high volume, continuous medication ... therapy to patients. Its 200 ml reservoir ... to 8 hours of nebulized medication delivery ...
Nebulizer Adapter Kit 6"...
... and Respiratory Products, ,Westmed designs, manufacturers ... Anesthesia and Respiratory professionals. Our mission is ... the clinician's ability to deliver quality medical ... bottom line. , ,Our web site ...
... and Respiratory Products, ,Westmed designs, manufacturers ... Anesthesia and Respiratory professionals. Our mission is ... the clinician's ability to deliver quality medical ... bottom line. , ,Our web site ...
Medicine Products: